Posts by Sandra Ansanay-Alex
SOPHiA GENETICS raises USD 57.5 million through a public offering
SOPHiA GENETICS, based in Canton of Vaud, announced the completion of its underwritten public offering, with total gross proceeds of $57.5 million, before deducting underwriting discounts, commissions and estimated offering expenses. The company sold 12,104,900 ordinary shares at $4.75 per share, according to a press release. The share is currently trading at $5.46, close to…
Read MoreDETECTRA and TUUS Solutions Receive a FIT Support
The Foundation for Innovation and Technology (FIT) is supporting two new life sciences startups in the Vaud region with Tech Seed loans. DETECTRA receives CHF 100’000 to develop its solution for remote monitoring of joint inflammation in patients with inflammatory arthritis. TUUS Solutions has received a CHF 100’000 loan to advance its dietary gel, designed…
Read MoreThree Leadership Appointments Shape Western Switzerland’s Health Landscape
June 2026 has brought a wave of significant leadership changes across Western Switzerland’s healthcare and life sciences sector, at Fondation La Source, Clinique Genolier, and at the European Association for Cancer Research (EACR). At the Clinique de Genolier, Aurélie Meynet has been appointed CEO, succeeding Stanley Hautdidier, who moves on to lead the newly created…
Read MoreMeditronFO: EPFL Launches the First Fully Transparent Medical AI Model
As artificial intelligence becomes increasingly prevalent in doctors’ surgeries and hospitals, one question arises: can we trust systems whose inner workings remain opaque? The LiGHT Laboratory (Laboratory for Intelligent Global Health Technologies) at EPFL , led by Professor Mary-Anne Hartley, has just released MeditronFO, a ‘Fully Open’ medical AI architecture — one that is entirely…
Read MoreOpen-I
Open-I is taking place on 26 November 2026 in Zurich Open-i brings together the key players in Switzerland’s innovation ecosystem: leading SMEs, start-ups, investors, corporates, academia, policymakers and the next generation of talent. The focus is on exchange, inspiration and tangible collaboration. Open-i shows how scientific insights can become new business models, market-ready solutions and…
Read MoreImmitra Bio receives CHF 150,000 from Venture Kick
The ETH spin-off and Geneva-based company Immitra Bio has received CHF 150,000 from Venture Kick to develop a new treatment approach for rare genetic diseases. The biotech startup aims to replace complex stem cell transplantation procedures with a single injection, making potentially curative therapies more accessible to patients worldwide. More than 7,000 rare genetic diseases…
Read MoreActival Shines at >>venture>> 2026 Award Ceremony
The annual >>venture>> Awards, held at the Swiss Tech Convention Centre at EPFL in Lausanne in front of around 300 guests, once again showcased the depth of Switzerland’s innovation ecosystem. This year, the Swiss Health Valley had reason to celebrate: Actival won the Medtech & Healthtech vertical. Actival, a spin-off from CSEM and the only…
Read MoreNIRLAB Acquired by 908 Devices
NIRLAB, the Swiss startup behind a handheld near-infrared (NIR) spectroscopy platform, has been acquired by 908 Devices. The ＄23 Million deal marks a major milestone for the Vaud-based company that, in just five years, has expanded into around fifty countries worldwide. By joining forces with US company 908 Devices, NIRLAB combines its AI-powered, cloud-connected NIR…
Read MoreAC Immune Receives $4 million from The Vijay and Marie Goradia Charitable Foundation
AC Immune SA, a Swiss clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, announced it will receive a research grant of $4 million from The Vijay and Marie Goradia Charitable Foundation. The grant will support extending Part 1 of the ongoing Phase 2 VacSYn trial of ACI-7104, AC Immune’s anti-alpha-synuclein (a-syn) active immunotherapy, in…
Read MorePrecise Health Gets a CHF 900’000 Innosuisse Grant
The Valais-based startup and EPFL spin out will use the funds to develop PhageMatch™, an AI powered platform that helps clinicians identify phages in partnership with University of Geneva (UNIGE) and University Hospital of Geneva (HUG). Antimicrobial resistance (AMR) is often described as the new cancer: left unchecked, it is projected to cause 10 million…
Read More